Abivax Shares Drop 4.92% at Close Despite Annual Performance of +1131%
Abivax shares fell by 4.92% on Wednesday, December 3, closing at 96.60 euros after opening at 101.60 euros the previous day. Despite this daily decline, the French biotech still shows a spectacular annual increase of 1131%, driven by the clinical success of its drug candidate Obefazimod.
Short-Term Volatility Amid Long-Term Gains
The stock experienced a downturn with only 0.15% of its capital traded, indicating relatively restrained volumes. Over the week, the decline has intensified to 10.89%, marking a consolidation phase after a remarkable 40% surge over three months. This short-term volatility is part of a broader reevaluation of the stock, which was trading around 7.84 euros a year ago before the publication of positive Phase 3 ABTECT trial results last July. The 50-day moving average is now at 86.58 euros, a level surpassed by the current price, while the 200-day moving average stands at 39.56 euros, reflecting a radical transformation in the stock's trajectory in 2025. Technically, the stock is trading within a Bollinger band range between 81.57 euros (lower bound) and 115.96 euros (upper bound), placing the current price in the median zone of this channel. The RSI at 61 suggests a still positive momentum without overbought signals, and the MACD shows a slightly bullish setup with a MACD line at 5.76 above the signal line at 5.65. These indicators reflect a technically constructive dynamic despite the weekly correction, with the stock retaining rebound potential towards major resistance at 111.80 euros. The identified support at 76.10 euros is a vigilance threshold for investors.
Outperforming the CAC 40
Abivax's performance starkly contrasts with that of the CAC 40, which only gained 0.16% in the session and 11.75% over the year. This massive outperformance is due to the promising results of clinical trials on Obefazimod for the treatment of ulcerative colitis, which propelled the stock to historical highs during the summer of 2025. The biotech also completed a record fundraising of 747.5 million dollars on the Nasdaq in July, significantly strengthening its cash reserves to fund development phases up to a potential commercialization expected in 2027. The recent history of the stock reveals an insider transaction with a purchase of 35,456 shares by an executive, generally interpreted as a sign of confidence in the company's prospects. The negative beta of -0.41 further indicates a significant decorrelation with market movements, a typical characteristic of biotech values whose evolution depends more on clinical and regulatory catalysts than on the global economic situation.
Navigating Regulatory Milestones Amid Volatility
The one-month volatility stands at 17.15%, reflecting the inherent uncertainty in the biotechnology sector and expectations surrounding upcoming regulatory milestones. Abivax still has to present the results of the 44-week maintenance study, expected in the second quarter of 2026, before it can file for marketing authorization with the FDA and EMA. These crucial deadlines partly explain the erratic movements of the stock, between phases of euphoria and profit-taking as observed this week. Without immediate news catalysts on December 3, the session's decline appears as a technical adjustment after a prolonged upward sequence. Investors seem to be adopting a cautious stance while waiting for new clinical or regulatory developments that could consolidate the current valuation, which now places Abivax among the most capitalized French biotechs in the market with approximately 7.8 billion euros in capitalization.
